Boehringer backs $33M can­cer vac­cine play at Switzer­land's AMAL Ther­a­peu­tics

A can­cer vac­cine de­vel­op­er spun out of the Uni­ver­si­ty of Gene­va has gar­nered €29 mil­lion ($32.7 mil­lion) to fu­el its dri­ve in­to the clin­ic.

AMAL Ther­a­peu­tics man­aged to con­vince all the in­vestors who col­lec­tive­ly gave €8 mil­lion last Sep­tem­ber to step up their com­mit­ment in this sec­ond clos­ing of the Se­ries B, fea­tur­ing co-lead­ers Boehringer In­gel­heim Ven­ture Fund, Bio­Med Part­ners and Helsinn In­vest­ment Fund in ad­di­tion to VI Part­ners, Schroder Ad­veq and High-Tech Grün­der­fonds.

Madi­ha Der­ouazi

With a plat­form tech called KISI­MA de­signed to pack a cell-pen­e­trat­ing pep­tide for anti­gen de­liv­ery, an ad­ju­vant­i­ng TLR- pep­tide ag­o­nist and a mul­ti-anti­genic car­go in­to one sin­gle vac­cine, the biotech says it is open­ing up a new class of can­cer vac­cines that can stoke an im­mune re­sponse in a broad­er spec­trum of pa­tients than the pre­vi­ous gen­er­a­tion could.

“KISI­MA al­lows prim­ing of both helper and killer cells for var­i­ous anti­gens and for var­i­ous HLA re­stric­tions, CEO Madi­ha Der­ouazi wrote in an email. She went on to ex­plain: “One mech­a­nism of im­mune es­cape by tu­mour cells is down reg­u­la­tion of anti­gen ex­pres­sion or of HLA pre­sen­ta­tion, hav­ing both mul­ti-anti­genic and tar­get­ing var­i­ous HLA would al­low to cir­cum­vent this im­mune es­cape mech­a­nisms.”

The first test will be in stage IV metasta­t­ic col­orec­tal can­cer, as Der­ouazi and her team of 15 steer the lead prod­uct can­di­date ATP128 to­ward clin­i­cal proof-of-con­cept across the US and Eu­rope, ex­pect­ed to be­gin in sum­mer 2019.

A sea­soned re­searcher in the field, Der­ouazi first de­vised the cell-pen­e­trat­ing pep­tide-based vac­cine at the Lab­o­ra­to­ry of Tu­mour Im­munol­o­gy at the Uni­ver­si­ty of Gene­va.

AMAL al­so says that its can­cer vac­cine — like many of its coun­ter­parts — makes good com­bi­na­tions with oth­er im­mune mod­u­la­tion agents, which is why it’s test­ing ATP128 with an an­ti-PD1 in its first-in-hu­man stud­ies. It will now have to prove that its ap­proach can find a place in the wave of next-gen can­cer vac­cines be­ing pro­gressed, in­clud­ing mR­NA ef­forts at Mod­er­na and BioN­Tech as well as the per­son­al­ized route ad­vanced by Neon and Grit­stone.

Con­quer­ing a silent killer: HDV and Eiger Bio­Phar­ma­ceu­ti­cals

Hepatitis delta, also known as hepatitis D, is a liver infection caused by the hepatitis delta virus (HDV) that results in the most severe form of human viral hepatitis for which there is no approved therapy.

HDV is a single-stranded, circular RNA virus that requires the envelope protein (HBsAg) of the hepatitis B virus (HBV) for its own assembly. As a result, hepatitis delta virus (HDV) infection occurs only as a co-infection in individuals infected with HBV. However, HDV/HBV co-infections lead to more serious liver disease than HBV infection alone. HDV is associated with faster progression to liver fibrosis (progressing to cirrhosis in about 80% of individuals in 5-10 years), increased risk of liver cancer, and early decompensated cirrhosis and liver failure.
HDV is the most severe form of viral hepatitis with no approved treatment.
Approved nucleos(t)ide treatments for HBV only suppress HBV DNA, do not appreciably impact HBsAg and have no impact on HDV. Investigational agents in development for HBV target multiple new mechanisms. Aspirations are high, but a functional cure for HBV has not been achieved nor is one anticipated in the forseeable future. Without clearance of HBsAg, anti-HBV investigational treatments are not expected to impact the deadly course of HDV infection anytime soon.

No­var­tis is ax­ing 150 ear­ly dis­cov­ery jobs as CNI­BR shifts fo­cus to the de­vel­op­ment side of R&D

Novartis is axing some 150 early discover jobs in Shanghai as it swells its staff on the drug development side of the equation in China. And the company is concurrently beefing up its investment in China’s fast-growing biotech sector with a plan to add to its investments in local VCs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,900+ biopharma pros reading Endpoints daily — and it's free.

No­var­tis is eye­ing a multi­bil­lion-dol­lar Med­Co buy­out as Jer­sey biotech nears NDA — re­ports

To get from Novartis’ US headquarters to the Medicines Company, you make a left out of a square concrete building on NJ-Route 10, follow it past the sun orange veranda of Jersey’s Hot Bagels and the inexplicable green Vermont cabin that houses the Whippany Railway Museum until you turn right and immediately arrive at a rectangular glass building. It should take you about 12 minutes.

Reports are out that Novartis may be making that trip. Amid a torrent of Phase III data burnishing MedCo’s chances at a blockbuster cholesterol drug,  Bloomberg News is reporting that Novartis is looking to acquire the Jersey-based biotech.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,900+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: In a land­mark first glimpse of hu­man da­ta from Ver­tex, CRISPR/Cas9 gene ther­a­py sig­nals ear­ly ben­e­fit

Preliminary data on two patients with blood disorders that have been administered with Vertex and partner CRISPR Therapeutics’ gene-editing therapy suggest the technology is safe and effective, marking the first instance of the benefit of the use of CRISPR/Cas9 technology in humans suffering from disease.

Patients in these phase I/II studies give up peripheral blood from which hematopoietic stem and progenitor cells are isolated. The cells are tinkered with using CRISPR/Cas9 technology, and the edited cells — CTX001 — are infused back into the patient via a stem cell transplant. The objective of CTX001 is to fix the errant hemoglobin gene in patents with two blood disorders: beta-thalassemia and sickle cell disease, by unleashing the production of fetal hemoglobin.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 65,900+ biopharma pros reading Endpoints daily — and it's free.

Badrul Chowdhury. FDA via Flickr

As­traZeneca los­es an­oth­er ex­ec­u­tive to biotech, as Badrul Chowd­hury moves to Savara

Another executive is migrating from the echelons of Big Pharma to the corridors of small biotech.

In April 2018, Badrul Chowdhury took his more than two decades of experience at the FDA to AstraZeneca, where he took on the role of senior vice president and chief physician-scientist for respiratory, inflammation and autoimmunity late-stage development in biopharmaceuticals R&D.

After about a year and a half in this role, Chowdhury is moving to a small Texas biotech called Savara, where he will serve as chief medical officer.

Yiannis Kiachopoulos and Artur Saudabayev, co-founders of Causaly

Lon­don AI up­start, which counts No­var­tis as a cus­tomer, can teach your com­put­er to read

When Amazon developed a machine-learning tool to make its recruitment process more efficient — the man-made system absorbed the gender-bias of its human makers, and the project was aborted. In the field of biopharmaceuticals, the way researchers train their machine learning algorithms can skew the outcome of predictions. But before those predictions can be made, the engine must learn to read to make sense of explosive volume of knowledge out there.

Burt Adelman. Novo Ventures

Here's a $25M seed fund aimed at back­ing some brash new drug ideas out of the Broad

As a former academic and a seasoned drug developer, Burt Adelman knew when he was recruited as a senior advisor to Novo Ventures in 2017 that one of his key priorities needs to be introducing the fund to the network he was so deeply embedded in.

“I was thinking long and hard on how can I, as a Boston insider, help Novo really get inside the ecosystem of Boston biotech?” he recalled in an interview with Endpoints News.

Welling­ton lines up a $393M bankroll for its next round of pri­vate biotech bets — and they’re like­ly think­ing big

Wellington Management made some uncustomary waves at the beginning of the year when it threw its considerable weight against Bristol-Myers Squibb’s $74 billion Celgene buyout. But after Bristol-Myers’ biggest investor conceded that game to the influential proxy firms involved, they’re now going to end the year by rolling out a big new investment fund for a new stable of fledgling biotechs on the private side of the industry.

As uter­ine race with Ab­b­Vie heats up, My­ovant eyes FDA ap­proval with tri­al re­sults from prostate can­cer

Myovant has long had a secret weapon in its uterine rivalry with AbbVie: Men.

While the small Swiss biotech has jockeyed with the Illinois-based giant for a foothold in the endometriosis and uterine fibroid therapy market, the company has been developing the same lead compound, relugolix, for use in one of the most common cancers for the uterus-less: prostate cancer. Today, Myovant is out with positive topline results from its big Phase III trial on the gonadotropin-releasing hormone (GnRH) antagonist. They say they’ve reached every primary and secondary endpoint with p values less than .0001.